CO2022007910A2 - Tratamientos contra el cáncer dirigidos a las células madre cancerosas - Google Patents

Tratamientos contra el cáncer dirigidos a las células madre cancerosas

Info

Publication number
CO2022007910A2
CO2022007910A2 CONC2022/0007910A CO2022007910A CO2022007910A2 CO 2022007910 A2 CO2022007910 A2 CO 2022007910A2 CO 2022007910 A CO2022007910 A CO 2022007910A CO 2022007910 A2 CO2022007910 A2 CO 2022007910A2
Authority
CO
Colombia
Prior art keywords
cancer
compounds
stem cells
kits
compositions
Prior art date
Application number
CONC2022/0007910A
Other languages
English (en)
Inventor
Yushma Bhurruth-Alcor
Gregory Thomas Crimmins
Jesús Diaz Dennise Alexandra De
Caroline Mae Robb
Original Assignee
Remedy Plan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedy Plan Inc filed Critical Remedy Plan Inc
Publication of CO2022007910A2 publication Critical patent/CO2022007910A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se describen compuestos, métodos, composiciones, usos y kits que permiten tratar el cáncer. En algunas modalidades, los compuestos se usan para tratar enfermedades o trastornos. Los compuestos pueden tratar el cáncer dirigiéndose a las células madre cancerosas. En algunas modalidades, el cáncer es cáncer colorrectal, cáncer gástrico, tumor del estroma gastrointestinal, cáncer de ovario, cáncer de pulmón, cáncer de mama, cáncer de páncreas, cáncer de testículo, linfoma, cáncer de hígado, cáncer de endometrio, leucemia o mieloma múltiple. Se describen compuestos, métodos, composiciones, usos y kits que pueden usarse en la medicina regenerativa. Los compuestos que se utilizan en la descripción tienen la fórmula (0) y (I).
CONC2022/0007910A 2019-11-06 2022-06-03 Tratamientos contra el cáncer dirigidos a las células madre cancerosas CO2022007910A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962931531P 2019-11-06 2019-11-06
PCT/US2020/059329 WO2021092322A1 (en) 2019-11-06 2020-11-06 Cancer treatments targeting cancer stem cells

Publications (1)

Publication Number Publication Date
CO2022007910A2 true CO2022007910A2 (es) 2022-08-19

Family

ID=73643356

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0007910A CO2022007910A2 (es) 2019-11-06 2022-06-03 Tratamientos contra el cáncer dirigidos a las células madre cancerosas

Country Status (12)

Country Link
US (1) US20230023124A1 (es)
EP (1) EP4055008A1 (es)
JP (1) JP2022553865A (es)
KR (1) KR20220110744A (es)
CN (1) CN114929672A (es)
AU (1) AU2020378067A1 (es)
BR (1) BR112022008753A2 (es)
CA (1) CA3157315A1 (es)
CO (1) CO2022007910A2 (es)
IL (1) IL292718A (es)
MX (1) MX2022005445A (es)
WO (1) WO2021092322A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022273050A1 (en) * 2021-05-13 2023-11-09 Remedy Plan, Inc. Nampt inhbitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
WO2008016643A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
CA2872652A1 (en) 2012-05-07 2013-11-14 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
EP2983659B1 (en) 2013-04-09 2019-11-20 Massachusetts Institute of Technology Drug delivery polymer and uses thereof
WO2019213570A1 (en) * 2018-05-04 2019-11-07 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells

Also Published As

Publication number Publication date
EP4055008A1 (en) 2022-09-14
WO2021092322A1 (en) 2021-05-14
IL292718A (en) 2022-07-01
US20230023124A1 (en) 2023-01-26
JP2022553865A (ja) 2022-12-26
KR20220110744A (ko) 2022-08-09
AU2020378067A1 (en) 2022-05-26
CA3157315A1 (en) 2021-05-14
MX2022005445A (es) 2022-08-10
CN114929672A (zh) 2022-08-19
BR112022008753A2 (pt) 2022-07-19

Similar Documents

Publication Publication Date Title
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
CO2020003478A2 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
EA201991622A1 (ru) Комплексная терапия для лечения рака
NZ771886A (en) Purinone compounds and their use in treating cancer
MX2018015094A (es) Derivados de carbonucleosidos sustituidos utiles como agentes antineoplasicos.
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
NZ726365A (en) Combinations for treating cancers
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
EA201790332A1 (ru) Дополнительная терапия 25-гидроксивитамином d
WO2019126739A8 (en) Pyrvinium pamoate anti-cancer therapies
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
CY1121885T1 (el) Αντι-ογκικες ενωσεις
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
BR112022003165A2 (pt) Método de tratamento de cânceres associados a kras
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
EA201400595A1 (ru) Морфолинилбензотриазины для применения в лечении рака
CO2022007910A2 (es) Tratamientos contra el cáncer dirigidos a las células madre cancerosas
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
CO2022016819A2 (es) Compuestos novedosos útiles como inhibidores de poli(adp-ribosa) polimerasa (parp)
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES